University of Wisconsin–Madison

Category: Treatment and Clinical Trials

Addressing Cochrane’s Review on Amyloid-Targeting Treatments for Alzheimer’s Disease

Posted on

Amyloid-targeting monoclonal antibody treatments have ushered in a new era of Alzheimer’s disease therapies after decades of research and clinical trials. A recent review published by Cochrane, a global, independent, non-profit network of researchers, professionals, patients and carers regarded as a gold standard for producing and promoting trusted, high-quality health information, has a different perspective on these therapies. The review found these treatments produce “little to no difference” in cognition and offer few benefits while increasing risks for adverse effects. Drs. Cynthia Carlsson, a clinical trialist, David Wolk, a clinician, and Henrik Zetterberg, a biomarker and disease biology expert, join the podcast to break down the review and their concerns, as well as highlight how this review could impact clinical care, research and public policy.

Guests: Cynthia Carlsson, MD, MS, director, Wisconsin Alzheimer’s Institute, Clinical Core leader, Wisconsin Alzheimer’s Disease Research Center (ADRC), Louis A. Holland, Sr., Professor in Alzheimer’s Disease, geriatrician, University of Wisconsin (UW) School of Medicine and Public Health; David Wolk, MD, director, Penn ADRC, co-director, Penn Memory Center, co-director, Penn Institute on Aging, professor of neurology, University of Pennsylvania Perelman School of Medicine; and Henrik Zetterberg, MD, PhD, professor of neurochemistry, University of Gothenburg, visiting professor, UW–Madison and University College London, Biomarker Core co-leader, Wisconsin ADRC

Unpacking the U.S. POINTER Study

Posted on

The U.S. POINTER study is one of the first large-scale, randomized controlled clinical trials to focus on how lifestyle interventions impact dementia risk and cognitive decline. On a special bonus episode of Dementia Matters, Dr. Laura Baker joins the podcast to explain how the clinical trial came to be, what it found and what the next chapter of lifestyle intervention research and clinical trials looks like.

Guest: Laura Baker, PhD, professor, Gerontology and Geriatrics, Wake Forest University School of Medicine, principal investigator, U.S. POINTER Study

Training for Clinical Trials with the IMPACT-AD Program

Posted on

Are you a researcher interested in getting involved in Alzheimer’s disease and related dementias (ADRD) clinical trials? The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD, or IMPACT-AD, program brings investigators from around the world together for a week of professional development and education. IMPACT-AD co-directors Dr. Josh Grill and Dr. Rema Raman, as well as faculty member Dr. Maria Carrillo, join the podcast to explain what the program entails, their mission and more.

Guests: Josh Grill, PhD, director, Institute for Memory Impairments and Neurological Disorders, professor, University of California, Irvine (UCI), co-director, IMPACT-AD, Rema Raman, PhD, co-director, IMPACT-AD, director, Biostatistics Section and Recruitment, Engagement, and Retention Section, Alzheimer’s Therapeutic Research Institute (ATRI), professor of neurology, University of Southern California (USC), and Maria Carrillo, PhD, chief science officer, medical affairs lead, Alzheimer’s Association, co-principal investigator, Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET), co-principal investigator, Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS)

Clarifying the Alzheimer’s Disease Clinical Trials Landscape

Posted on

Clinical trials are essential for improving the lives of those diagnosed with Alzheimer’s disease and related dementias. With so many trials out there, it can be difficult for someone who’s interested in participating in research to know where to start. Dr. Jonathan Graff-Radford joins the podcast to discuss the ins and outs of clinical trials and the state of Alzheimer’s treatments today, as well as share some highlights from his presentation at the National Alzheimer’s Coordinating Center’s (NACC) 2025 Spring ADRC Meeting.

Guest: Jonathan Graff-Radford, MD, behavioral neurologist, associate professor, vice chair, Mayo Clinic Department of Neurology, co-investigator, Mayo Clinic Alzheimer’s Disease Research Center

Getting AHEAD of Alzheimer’s with Inclusive Clinical Trials

Posted on

Dementia Matters Special Series: Voices of Research Participants

When Ms. Carol Turner found out her family had a history of Alzheimer’s disease, she wanted to know how she could help herself and others with similar experiences. After learning about the AHEAD Study, which is testing a treatment that could delay memory loss before Alzheimer’s symptoms appear, she signed up to participate in this ground-breaking research. Ms. Turner joins the final episode in our Voices of Research Participants series to discuss her journey as a research participant, how she became an advocate for others in her community and the power of representation in clinical trials.

Guest: Ms. Carol Turner, AHEAD Study participant

Co-host: Sarah Walter, MSc, program administrator, Alzheimer’s Clinical Trials Consortium (ACTC) and Alzheimer’s Therapeutic Research Institute (ATRI)

Making an IMPACT: Advancing Alzheimer’s Disease Clinical Trials Through Workforce Development and Inclusivity

Posted on

Advances in Alzheimer’s disease clinical trials are accelerating rapidly, leading to new insights and disease-modifying therapies, but how does the field continue bolstering that momentum? For Dr. Rema Raman, it’s through improving inclusivity and training for early-career researchers. Recorded at the 2024 Alzheimer’s Disease & Related Dementias Research Day, Dr. Raman joins the podcast to discuss her work in research recruitment and retention, the importance of training the next generation of clinical trialists in dementia research with the IMPACT-AD program and more from her featured presentation.

Guest: Rema Raman, PhD, co-director, Institute of Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD), director, section of biostatistics, section of participant recruitment & retention section, Alzheimer’s Therapeutic Research Institute, professor of neurology, University of Southern California

Looking at Lecanemab’s Eligibility Guidelines and Prescription Process

Posted on

In the past few years, new therapies shown to slow the progression of Alzheimer’s disease in people in the early stages of the disease have been making their way through the U.S. Food and Drug Administration’s (FDA) approval process. With these treatments now available, there are a growing number of questions surrounding who is eligible to take these medications and what processes are needed to ensure they are prescribed safely and effectively. Host Dr. Nathaniel Chin examines the guidelines for geriatricians and clinicians prescribing lecanemab and breaks down the eligibility requirements necessary to receive this treatment.

Could Green Tea Hold the Key to New Alzheimer’s Treatments?

Posted on

Dr. Paul Seidler joins the podcast to discuss his recent study looking at the connection between molecules in green tea and tau proteins. He also discusses the impact those molecules have on preventing cognitive decline and how these findings could lead to new strategies for treating Alzheimer’s disease.

Guest: Paul Seidler, PhD, assistant professor, University of Southern California Mann School of Pharmacy and Pharmaceutical Sciences

Putting Lecanemab into Practice: A Clinician’s Perspective on the New Alzheimer’s Treatment

Posted on

On July 6, 2023, the U.S. Food and Drug Administration (FDA) granted full approval for the Alzheimer’s disease drug Leqembi (lecanemab-irmb), the first medicine shown to delay the course of the disease. Having gone through a rigorous approval process, the medication exemplifies a critical advancement in the ongoing battle to treat Alzheimer’s disease. Having already prescribed the treatment to real-life patients, Dr. Robert Przybelski joins the podcast to discuss his experience prescribing and administering lecanemab, what clinicians and patients should discuss when considering these treatments, and what is needed to integrate these treatments into the healthcare system.

Guest: Robert Przybelski, MD, MS, director, Geriatric Memory Clinics, UW Health, professor, Division of Geriatrics and Gerontology, University of Wisconsin School of Medicine and Public Health

Lecanemab, Clinical Trials, and the Importance of Clinical Meaningfulness

Posted on

On June 9, 2023, the Food and Drug Administration’s (FDA) advisory committee unanimously voted to approve lecanemab, moving the treatment one step closer to full FDA approval. In the lead up to the FDA’s official announcement expected in early July, Dr. Paul Aisen joins the podcast to discuss Alzheimer’s disease clinical trials. Aisen,  the founding director of the Alzheimer’s Therapeutic Research Institute (ATRI) and a leading figure in Alzheimer’s disease research for over three decades, talks about the Phase 3 clinical trials for lecanemab and gantenerumab and shares highlights from the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) conference.

Guest: Paul Aisen, MD, professor of neurology, Keck School of Medicine, University of Southern California, Director, Alzheimer’s Therapeutic Research Institute

A Closer Look At The Lecanemab Clinical Trials

Posted on

In a special episode of Dementia Matters, Drs. Cynthia Carlsson and Sterling Johnson join the podcast to discuss what they know from lecanemab’s clinical trials following the U.S. Food and Drug Administration’s (FDA) accelerated approval, granted on January 6, 2023.

Guests: Cynthia Carlsson, MD, MS, director, Wisconsin Alzheimer’s Institute, and Sterling Johnson, PhD, leader, Wisconsin Registry for Alzheimer’s Prevention (WRAP), associate director, Wisconsin Alzheimer’s Disease Research Center and Wisconsin Alzheimer’s Institute

Introducing Lecanemab, the Latest Alzheimer’s Disease Drug to Receive FDA Accelerated Approval

Posted on

Host Nathaniel Chin, MD, gives an overview of the new Alzheimer’s treatment Leqembi (lecanemab), and highlights results from the second and third phases of its clinical trials. On January 6, 2023, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease.

Breaking Down Medicare’s Proposed Decision on Aducanumab and Monoclonal Antibody Treatments

Posted on

On January 11, the Centers for Medicare and Medicaid Services (CMS) announced its much-anticipated coverage proposal for monoclonal antibody treatments that target amyloid for the treatment of Alzheimer’s disease. According to the proposed policy, this class of drugs, which includes aducanumab, also known by the brand name Aduhelm, would be covered for people with Medicare only if they are enrolled in qualifying clinical trials. Dr. Jason Karlawish joins the podcast to discuss the recent proposal, share his reaction to the decision, and tell us how this coverage policy could impact the development of other Alzheimer’s disease treatments in the future.

Guest: Jason Karlawish, MD, co-director, Penn Memory Center, professor of medicine, medical ethics and health policy, and neurology, University of Pennsylvania

Nasal Vaccine for Alzheimer’s Disease Enters Clinical Trial

Posted on

In November 2021, Brigham and Women’s Hospital in Boston launched the first human trial of a nasal vaccine for Alzheimer’s disease. Nearly 20 years of research went into developing the vaccine, which uses the immune system to clear Alzheimer’s disease-related proteins from the brain. Lead researcher Dr. Howard Weiner joins the podcast to discuss the science behind the vaccine and how it could introduce new ways of treating other neurodegenerative diseases in the future.

Guest: Howard Weiner, MD, professor of neurology, Harvard Medical School, co-director, Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital

How Close Are We to Curing Alzheimer’s Disease?

Posted on

For our 100th episode of Dementia Matters, Nina Silverberg, PhD, director of the Alzheimer’s Disease Research Centers (ADRC) Program at the National Institute on Aging (NIA), joins the podcast to offer an overview of the ADRC Program as well as insight into the state of Alzheimer’s Disease research and its future. The NIA funds more than 30 Alzheimer’s Disease Research Centers across the country, including the Wisconsin ADRC.

Guest: Nina Silverberg, PhD, National Institute on Aging